)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Tvardi Therapeutics
Tvardi Therapeutics (TVRD) investor relations material
Tvardi Therapeutics has been delisted
Tvardi Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary31 Mar, 2026
Executive summary
Advanced clinical pipeline with two STAT3 inhibitors: TTI-101 and next-generation TTI-109, targeting inflammatory and proliferative diseases.
Anticipated key clinical milestones in 2026, including topline data from healthy volunteer and liver cancer trials.
Interim results from the REVERT LIVER CANCER trial showed clinically meaningful activity for TTI-101.
Financial highlights
Research and development expenses decreased to $18.0M for 2025 from $23.7M in 2024, mainly due to lower TTI-101 clinical costs offset by higher TTI-109 development costs.
General and administrative expenses rose to $8.7M in 2025 from $4.5M in 2024, driven by increased professional fees post-merger.
Net loss for 2025 was $18.2M, improving from $29.4M in 2024.
Cash, cash equivalents, and short-term investments totaled $30.8M as of December 31, 2025.
Outlook and guidance
Cash runway expected to fund operations through clinical readouts and into Q4 2026.
Topline data from TTI-109 healthy volunteer study expected in Q2 2026; Phase 2 TTI-101 HCC trial data anticipated in H2 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Tvardi Therapeutics
- All-stock merger forms a STAT3-focused biotech with key clinical milestones expected in 2025.TVRD
M&A Announcement10 Jan 2026 - Biotech developing oral STAT3 inhibitors for fibrosis and cancer faces high risk, no revenue, and urgent capital needs.TVRDRegistration Filing28 Nov 2025
- Reverse merger, $5.5M Q3 loss, $36.5M cash, and key 2026 clinical milestones ahead.TVRDQ3 202513 Nov 2025
- Biotech developing oral STAT3 inhibitors for fibrosis and cancer, with no IPO proceeds to the company.TVRDRegistration Filing20 Oct 2025
- Q2 revenue fell 86% as NP program ended, staff cut 70%, and a strategic review began.TVRDQ2 202413 Oct 2025
- Biotech developing oral STAT3 inhibitors for fibrosis; IPO is resale, no proceeds to company.TVRDRegistration Filing7 Oct 2025
- Q2 profit from one-time gain, but long-term funding and viability remain key risks.TVRDQ2 202514 Aug 2025
- Revenue fell sharply as Cara shifted to strategic alternatives and faces Nasdaq delisting risk.TVRDQ3 202413 Jun 2025
- Cara faces steep losses and revenue decline, with its future dependent on a merger and asset sale.TVRDQ4 20249 Jun 2025
Tvardi Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage